NCT07184385View on ClinicalTrials.gov

A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2026

Primary Completion Date

June 30, 2027

Study Completion Date

September 30, 2027

Conditions
Long COVIDPost-COVID-19 ConditionPost-COVID SyndromePost-COVID Condition
Interventions
BIOLOGICAL

REGENECYTE

HPC, Cord Blood

BIOLOGICAL

Placebo

Normal Saline

All Listed Sponsors
lead

StemCyte, Inc.

INDUSTRY